Long-term survivors and gilteritinib safety beyond 1 year in patients with FLT3-mutated relapsed or refractory acute myeloid leukemia: ADMIRAL trial follow-up

被引：0

作者：

Perl, Alexander E. ^{[1
]}

Martinelli, Giovanni ^{[2
]}

Neubauer, Andreas ^{[3
]}

Berman, Ellin ^{[4
]}

Baer, Maria R. ^{[5
]}

Larson, Richard A. ^{[6
]}

Fathi, Amir T. ^{[7
]}

Yokoyama, Hisayuki ^{[8
]}

Hosono, Naoko ^{[9
]}

Hasabou, Nahla ^{[10
]}

Lu, Qiaoyang ^{[10
]}

Tiu, Ramon V. ^{[10
]}

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[2] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy

[3] Univ Klinikum Giessen & Marburg GmbH, Marburg, Germany

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[6] Univ Chicago, Chicago, IL 60637 USA

[7] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA

[8] Natl Hosp Org, Sendai Med Ctr, Sendai, Miyagi, Japan

[9] Univ Fukui, Fukui, Japan

[10] Astellas Pharma US Inc, Northbrook, IL USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH2021-OR

引用

页码：3 / 4

页数：2

共 50 条

[41] Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib (Vol 6, pg 2144, 2022)
Smith, C. C.
Levis, M. J.
Perl, A. E.
BLOOD ADVANCES, 2022, 6 (22) : 5886 - 5886
[42] Quizartinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: More Patients Make It to Transplant, but Are There Any Other Benefits?
Hunter, Bradley D.
TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (02): : 99 - 100
[43] Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia
Zucenka, Andrius
Griskevicius, Laimonas
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1227 - 1231
[44] Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Numan, Yazan
Abdel Rahman, Zaid
Grenet, Justin
Boisclair, Stephanie
Bewersdorf, Jan Philipp
Collins, Cailin
Barth, Dylan
Fraga, Martina
Bixby, Dale L.
Zeidan, Amer M.
Yilmaz, Musa
Desai, Pankil
Mannis, Gabriel
Deutsch, Yehuda E.
Abaza, Yasmin
Dinner, Shira
Frankfurt, Olga
Litzow, Mark
Al-Kali, Aref
Foran, James M.
Sproat, Lisa Z.
Jovanovic, Borko
Daver, Naval
Perl, Alexander E.
Altman, Jessica K.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : 322 - 328
[45] Postchemotherapy erythroid cannibalism in relapsed NPM1, FLT3-mutated acute myeloid leukemia
Chauhan, Richa
Kotwal, Jyoti
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 (02) : E80 - E81
[46] Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML
Ritchie, Ellen K.
Cella, David
Fabbiano, Francesco
Pigneux, Arnaud
Kanda, Yoshinobu
Ivanescu, Cristina
Pandya, Bhavik J.
Shah, Manasee V. V.
LEUKEMIA & LYMPHOMA, 2023, 64 (05) : 938 - 950
[47] PSYCHOMETRIC ANALYSIS OF PATIENT-REPORTED OUTCOME MEASURES IN FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Cella, D.
Corredoira, L.
Ivanescu, C.
Pandya, B. J.
Shah, M., V
VALUE IN HEALTH, 2020, 23 : S83 - S83
[48] Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3Mutated Acute Myeloid Leukemia
Daver, Naval
Perl, Alexander E.
Maly, Joseph
Levis, Mark
Ritchie, Ellen
Litzow, Mark R.
McCloskey, James
Smith, Catherine C.
Schiller, Gary J.
Bradley, Terrence
Tiu, Ramon V.
Naqvi, Kiran
Dail, Monique
Siddani, Satya
Wang, Jing
Chyla, Brenda
Lee, Paul
Altman, Jessica K.
BLOOD, 2021, 138
[49] Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
Pierre-Yves Dumas
Emmanuel Raffoux
Emilie Bérard
Sarah Bertoli
Marie-Anne Hospital
Maël Heiblig
Yohann Desbrosses
Caroline Bonmati
Cécile Pautas
Juliette Lambert
Corentin Orvain
Anne Banos
Florence Pasquier
Pierre Peterlin
Tony Marchand
Madalina Uzunov
Jamilé Frayfer
Pascal Turlure
Thomas Cluzeau
Eric Jourdan
Chantal Himberlin
Emmanuelle Tavernier
Alban Villate
Stephanie Haiat
Marie-Lorraine Chretien
Martin Carre
Sylvain Chantepie
Ioana Vaida
Mathieu Wemeau
Safia Chebrek
Gaelle Guillerm
Romain Guièze
Houria Debarri
Eve Gehlkopf
Kamel Laribi
Ambroise Marcais
Alberto Santagostino
Marie-Christine Béné
Ariane Mineur
Arnaud Pigneux
Hervé Dombret
Christian Récher
Leukemia, 2023, 37 : 91 - 101
[50] Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
Dumas, Pierre-Yves
Raffoux, Emmanuel
Berard, Emilie
Bertoli, Sarah
Hospital, Marie-Anne
Heiblig, Mael
Desbrosses, Yohann
Bonmati, Caroline
Pautas, Cecile
Lambert, Juliette
Orvain, Corentin
Banos, Anne
Pasquier, Florence
Peterlin, Pierre
Marchand, Tony
Uzunov, Madalina
Frayfer, Jamile
Turlure, Pascal
Cluzeau, Thomas
Jourdan, Eric
Himberlin, Chantal
Tavernier, Emmanuelle
Villate, Alban
Haiat, Stephanie
Chretien, Marie-Lorraine
Carre, Martin
Chantepie, Sylvain
Vaida, Ioana
Wemeau, Mathieu
Chebrek, Safia
Guillerm, Gaelle
Guieze, Romain
Debarri, Houria
Gehlkopf, Eve
Laribi, Kamel
Marcais, Ambroise
Santagostino, Alberto
Bene, Marie-Christine
Mineur, Ariane
Pigneux, Arnaud
Dombret, Herve
Recher, Christian
LEUKEMIA, 2023, 37 (01) : 91 - 101

← 1 2 3 4 5 →